CompletedPhase 3

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)

United States278 participantsStarted 2014-03-31

Plain-language summary

This study (ARD-3150-1201, ORBIT-3) will evaluate the safety and efficacy of inhaled Pulmaquin (ciprofloxacin dispersion for inhalation) compared to inhaled placebo in subjects who have a confirmed diagnosis of non-cystic fibrosis (non-CF) bronchiectasis with a history of pulmonary exacerbations and chronic P. aeruginosa infections.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Verified bronchiectasis diagnosis * Pseudomonas aeruginosa lung infection Exclusion Criteria: * Cystic Fibrosis

What they're measuring

Time to first exacerbation

Timeframe: One Year

Trial details

NCT IDNCT01515007

SponsorAradigm Corporation

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2016-08-17

View on ClinicalTrials.gov More Non Cystic Fibrosis Bronchiectasis trials